T-cell receptor-CD3 complex and CD28 costimulatory receptor (TCR/CD3-CD28)

The CD3/CD28 complex is the primary molecular engine for T-cell activation, consisting of the T-cell receptor (TCR)-associated CD3 subunits and the CD28 costimulatory receptor (UniProt P07766, P10747). CD3 mediates the initial Signal 1 upon recognition of antigenic peptides presented by MHC molecules, while CD28 provides the essential Signal 2 by binding to B7-1 (CD80) or B7-2 (CD86) ligands on professional antigen-presenting cells like dendritic cells (PubMed 19413505). This dual signaling is required to prevent T-cell anergy and drive robust proliferation, cytokine secretion, and differentiation into effector cells (StatPearls, Physiology, T Cell Receptor). In therapeutic contexts, this complex is targeted by monoclonal antibodies to either deplete T cells (e.g., Muromonab-CD3) or modulate their activity in autoimmune diseases (e.g., Teplizumab) and transplantation (e.g., Abatacept) (FDA). Furthermore, the engagement of these receptors by autologous dendritic cells is the basis for cellular vaccines such as Sipuleucel-T, which aims to prime the immune system against specific tumor antigens (Nature Reviews Immunology). However, potent activation of this complex carries significant risks, most notably cytokine release syndrome, which necessitates careful clinical monitoring (PubMed 29296020).

Other names

CD3/CD28 signaling complexT-cell activation unitSignal 1 and Signal 2 complexTCR-CD3/CD28 axis

Modulation of T-lymphocyte activity through the simultaneous or sequential engagement of the TCR-CD3 signaling complex and the CD28 costimulatory receptor to either induce immune activation or promote tolerance.